HOME HELP FEEDBACK SUBSCRIPTIONS ALL ISSUES SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pomara, N. Articles by Mehta, P. D. Search for Related Content PubMed PubMed Citation Articles by Pomara, N. Articles by Mehta, P. D.

Selective Reductions in Plasma Aß 1-42 in Healthy Elderly Subjects During Longitudinal Follow-Up

A Preliminary Report

Received December 23, 2003; revised November 23, 2004; accepted January 31, 2005. From the Geriatric Psychiatry Program, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY (NP, LMW, JJS), the Dept. of Psychiatry, New York Univ. School of Medicine, New York, NY (NP, JJS), and the Dept. of Immunology, Institute for Basic Research in Developmental Disabilities, Staten Island, NY (PDM). Send correspondence and reprint requests to Nunzio Pomara, M.D., Geriatric Psychiatry Program, Nathan S. Kline Institute, 140 Old Orangeburg Rd., Bldg. 35, Orangeburg, NY 10962. e-mail: pomara{at}nki.rfmh.org
© 2005 American Association for Geriatric Psychiatry

Objective: Longitudinal changes in plasma beta amyloid protein 1-42 and 1-40 (Aß42 and Aß40) levels and possible relationships with cognitive decline and apolipoprotein (APOE) genotype were studied in healthy elderly individuals. Methods: Authors determined cognitive level and plasma Aß40 and Aß42 levels twice, approximately 4 years apart, in 34 elderly subjects. Results: Analyses revealed a selective reduction in Aß42 levels at follow-up, which were not modulated by the 4 allele. Greater reductions and higher baseline plasma Aß42 levels were associated with reductions in cognitive scores. Conclusions: Alterations in plasma Aß42 levels may be associated with subtle cognitive decline in elderly subjects without dementia.

Key Words: Amyloid Beta Proteins • Longitudinal Studies • Dementia • Apolipoprotein 4 Alleles

This article has been cited by other articles:

				X. Sun, D. C. Steffens, R. Au, M. Folstein, P. Summergrad, J. Yee, I. Rosenberg, D. M. Mwamburi, and W. Q. Qiu Amyloid-Associated Depression: A Prodromal Depression of Alzheimer Disease? Arch Gen Psychiatry, May 1, 2008; 65(5): 542 - 550. [Abstract] [Full Text] [PDF]

				H. A. Crystal and P. Davies Toward a plasma marker for Alzheimer disease: Some progress, but still a long way to go Neurology, February 19, 2008; 70(8): 586 - 587. [Full Text] [PDF]

				N. Ertekin-Taner, L. H. Younkin, D. M. Yager, F. Parfitt, M. C. Baker, S. Asthana, M. L. Hutton, S. G. Younkin, and N. R. Graff-Radford Plasma amyloid {beta} protein is elevated in late-onset Alzheimer disease families Neurology, February 19, 2008; 70(8): 596 - 606. [Abstract] [Full Text] [PDF]

				N. Schupf, B. Patel, D. Pang, W. B. Zigman, W. Silverman, P. D. Mehta, and R. Mayeux Elevated Plasma beta-Amyloid Peptide Abeta42 Levels, Incident Dementia, and Mortality in Down Syndrome Arch Neurol, July 1, 2007; 64(7): 1007 - 1013. [Abstract] [Full Text] [PDF]